August 02, 2022
Oxford, UK and Cleveland, Ohio, USA – The Oxford-Harrington Rare Disease Centre (OHC), a partnership of the University of Oxford and Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, today announced its support of a novel treatment for Duchenne muscular dystrophy, a rare neuromuscular disease...
Continue Reading
August 08, 2022
Richard Kramer, PhD, Hopes to Help Patients with Retinitis Pigmentosa Continue Reading
July 25, 2022
Harrington Discovery Institute and the American Society for Clinical Investigation seek nominations to recognize an outstanding achievement by a physician-scientist Continue Reading
June 13, 2022
Grant programme seeks to advance novel therapies for rare diseases Continue Reading
June 01, 2022
Focus on epigenetics, neurovascular health, and other novel approaches Continue Reading
April 28, 2022
More than 150 drug discovery projects now supported by Harrington Discovery Institute Continue Reading
April 25, 2022
Epitopea, a transatlantic cancer Immunotherapeutics company, announces a $13.6M seed investment with support from Harrington Discovery Institute/University Health Holdings to create transformational immunotherapies that target broad cancer patients. Continue Reading
March 24, 2022
2022 Harrington Prize for Innovation in Medicine Recognizes Breakthrough Innovations in the Use of Human Antibodies to Treat COVID-19March 24, 2022, Cleveland, Ohio – The ninth annual Harrington Prize for Innovation in Medicine has been jointly awarded to James E. Crowe, Jr., MD, Director, Vanderbilt Vaccine Center and... Continue Reading
February 23, 2022
February 23, 2022, CLEVELAND, Ohio USA - Harrington Discovery Institute at University Hospitals is now accepting the Letters of Intent for the 2023 Harrington Scholar-Innovator Award for physician-scientists. The award offers successful applicants financial resources and expertise to advance their discoveries toward clinical... Continue Reading
December 09, 2021
New Orleans, LA – LSU Health New Orleans entered into an exclusive option and license agreement with Takeda Pharmaceutical Company Limited (“Takeda”) granting Takeda the exclusive right to develop further a technology invented at LSU Health New Orleans with the aim to discover potential therapeutics to treat rare... Continue Reading
October 18, 2021
INDIANAPOLIS— A group of researchers led by Indiana University School of Medicine’s , has been awarded a research program project grant (P01) from the National Heart, Lung and Blood Institute. The award amounts to just over $12 million over the next five years and will fund the development of personalized therapeutic... Continue Reading